Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.

MLA

Luo, Jing, et al. “Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.” Journal of General Internal Medicine, vol. 37, no. 14, Nov. 2022, pp. 3562–69. EBSCOhost, https://doi.org/10.1007/s11606-021-07331-1.

APA

Luo, J., Feldman, R., Rothenberger, S., Korytkowski, M., Fischer, M. A., & Gellad, W. F. (2022). Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. Journal of General Internal Medicine, 37(14), 3562–3569. https://doi.org/10.1007/s11606-021-07331-1

Chicago

Luo, Jing, Robert Feldman, Scott Rothenberger, Mary Korytkowski, Michael A Fischer, and Walid F Gellad. 2022. “Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.” Journal of General Internal Medicine 37 (14): 3562–69. doi:10.1007/s11606-021-07331-1.